U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 17, 2012
GLOBAL IMMUNE TECHNOLOGIES, INC.
(Exact Name of registrant as specified in
|(State of Incorporation)
||Commission File No.
2809 Great Northern Loop, Suite 100,
Missoula, MT 59808-1749
of principal executive offices) (Zip Code)
Registrant’s telephone number, (
406 ) 322 - 3844
(Registrant’s former name and address)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions below:
¨ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17CFR 240-14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240-13e-4(c))
SECTION 1. Registrants Business and Operations
Item 1.02 Termination of Material Definitive Agreement
On March 20, 2012 at a meeting of the Board of Directors, the
meeting terminated the Definitive Agreement with Institute For Applied Technology and the Joint Venture known as RENON, GmbH.,
and to cancel and return to treasury the 92,000,000 shares of Company Common Stock issued in the transaction. The Company will
now have 22,890,153 shares of Common Stock issued and outstanding.
SECTION 2. Financial Information
SECTION 3. Securities and Trading Markets
SECTION 4. Matters Related to Accountants and Financial Statements
SECTION 5. Corporate Governance and Management
Item 5.01 Changes in Control of Registrant
As referenced in Item 1.02 the 92,000,000 shares of Common Stock
will be canceled and returned to treasury in conjunction with terminating the purchase and joint venture agreements. This was publically
announced in a press release on March 20, 2012. Under Wyoming statutes the shares are issued as non-voting until a majority of
then existing shareholders approve the change of control. As a formality, the upcoming shareholder meeting will vote down the acceptance
of the issuance and officially cancel the shares previously issued.
Item 5.02 Departure of Directors or Principal
Officers; Election of Directors; Appointment of Principal Officers
On March 20, 2012 at a Meeting of the Board of Directors, the
meeting accepted the resignation of four directors, Donald L. Perks, Uwe Vincenz, Christoph Ehses and Gerd Schroth leaving Alejandro
Bellapart the sole director and Donald L. Perks the acting president.
On May 23, 2012 at a meeting of the Board of Directors sole
director Alejandro Bellapart elected Jeffrey R. Bruhjell director and appointed him president, CEO, Secretary & CFO. Mr.
Perks stepped down as Acting President. The size
of the Board of Directors is now two.
On September 17, 2012 at a meeting of the Board of Directors,
the meeting elected Mr. Serge Talon as director and appointed him president & CEO and Mr. Bruhjell Secretary & CFO. The size of the Board of Directors is now three.
Mr. Talon is an experienced executive originally from Quebec.
Serge joined the US Army and served in Vietnam. Mr. Talon received Naturalized US Citizenship for his service and nowadays makes
his home in Hollywood, Florida.
Neither Mr. Bellapart, Mr. Bruhjell or Mr. Talon will be paid
for their services as directors at this time.
SECTION 6. [Reserved]
SECTION 7. Regulation FD
Item 7.01 Regulation FD Disclosure
Except for the historical information presented in this document,
the matters discussed in this Form 8-K, or otherwise incorporated by reference into this document, contain "forward-looking
statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are identified
by the use of forward-looking terminology such as "believes", "plans", "intend", "scheduled",
"potential", "continue", "estimates", "hopes", "goal", "objective",
expects", "may", "will", "should" or "anticipates" or the negative thereof or other
variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. The safe harbor
provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
amended, apply to forward-looking statements made by the Registrant. The reader is cautioned that no statements contained in this
Form 8-K should be construed as a guarantee or assurance of future performance or results. These forward-looking statements involve
risks and uncertainties, including those identified within this Form 8-K. The actual results that the Registrant achieves may differ
materially from any forward-looking statements due to such risks and uncertainties. These forward-looking statements are based
on current expectations, and the Registrant assumes no obligation to update this information. Readers are urged to carefully review
and consider the various disclosures made by the Registrant in this Form 8-K and in the Registrant's other reports filed with the
Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that may affect the Registrant's
business. Note: Information in this report furnished pursuant to Item 7 shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The
information in this current report shall not be incorporated by reference into any registration statement pursuant to the Securities
Act of 1933, as amended. The furnishing of the information in this current report is not intended to, and does not, constitute
a representation that such furnishing is required by Regulation FD or that the information this current report contains is material
investor information that is not otherwise publicly available.
Safe Harbor for Failure to File
Because of the difficulty inherent in quick judgments regarding
materiality and need to file under some of the new Form 8-K items, the SEC has adopted a limited safe harbor that will protect
the company from (1) antifraud liability under Exchange Act Section 10(b) and Rule 10b-5 or (2) loss of eligibility to use abbreviated
registration statement forms (i.e., Forms S-2 and S-3) under the Securities Act of 1933, solely as a result of failure to make
a timely filing on Form 8-K. The failure-to-file safe harbor relates only to Items 1.01, 1.02, 2.03, 2.04, 2.05, 2.06 and 4.02(a)
of amended Form 8-K, each of which requires management to make assessments regarding materiality or a determination regarding the
occurrence of a triggering event.
The antifraud liability safe harbor relates only to the failure
to file and not to misstatements or omissions that are made in Form 8-K disclosure. The liability safe harbor extends only until
the due date of the company's next periodic report (in which the required disclosures must be made).
SECTION 8. Other Events
The Company’s address remains Suite 100, 2809 Great Northern
Loop, Missoula, MT 59808-1749. The new telephone number is (406) 322-3844.
SECTION 9. Financial Statements and Exhibits
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
||Global Immune Technologies, Inc.|
|Dated: September 17, 2012
||/S/Jeffrey R. Bruhjell|
||By: Jeffrey R. Bruhjell|
||Title: Secretary & CFO|